Reimagining Medicine Q2 2023 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Financial performance Immunology ianalumab - BAFF-R inhibitor Conclusions Appendix Innovation: Clinical trials Neuroscience Oncology ianalumab - BAFF-R inhibitor Indication NCT05349214 NEPTUNUS-2 (CVAY736A2302) Sjögren's syndrome Indication NCT05350072 NEPTUNUS-1 (CVAY736A2301) Sjögren's syndrome Phase Phase 3 Phase Phase 3 Patients 489 Patients 285 Primary Outcome Change from baseline in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo Measures Primary Outcome Measures Arms Arms Intervention Target Patients Arm 1: Experimental - ianalumab exposure level 1 Arm 2: Experimental - ianalumab exposure level 2 Arm 3: Placebo comparator Patients with active Sjogren's syndrome Readout Milestone(s) Primary 2026 Publication TBD 55 Investor Relations | Q2 2023 Results References Abbreviations Other Intervention Target Patients Change from baseline in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo Arm 1: Experimental - ianalumab Arm 2: Placebo comparator Patients with active Sjogren's syndrome Readout Milestone(s) Primary 2026 Publication TBD NOVARTIS | Reimagining Medicine

View entire presentation